NBY vs. BCTX, OMGA, ACXP, MYNZ, SNSE, TXMD, FLGC, PMCB, CHRO, and TLPH
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include BriaCell Therapeutics (BCTX), Omega Therapeutics (OMGA), Acurx Pharmaceuticals (ACXP), Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), Flora Growth (FLGC), PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs.
BriaCell Therapeutics (NASDAQ:BCTX) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
BriaCell Therapeutics has higher earnings, but lower revenue than NovaBay Pharmaceuticals. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics received 11 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 1.75% of users gave NovaBay Pharmaceuticals an outperform vote.
15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 5.7% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
BriaCell Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.
BriaCell Therapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. BriaCell Therapeutics' return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.
BriaCell Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 617.49%. NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential upside of 34.92%. Given BriaCell Therapeutics' higher probable upside, equities analysts clearly believe BriaCell Therapeutics is more favorable than NovaBay Pharmaceuticals.
In the previous week, BriaCell Therapeutics' average media sentiment score of 1.58 beat NovaBay Pharmaceuticals' score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the media.
Summary
BriaCell Therapeutics beats NovaBay Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 2/22/2025 by MarketBeat.com Staff
